C-Path's International Neonatal Consortium (INC), is held in collaboration with partners at the US Food and Drug Administration and industry and academic stakeholders. This two-day annual scientific meeting will be held in a virtual format.
What to expect
The first day will focus on the rapidly evolving field of cell and gene therapy in neonatal population. The current landscape of gene therapy clinical trials in neonates will be discussed, followed by perspectives from stakeholders including industry, academic, regulator, and parent partners of INC. Subsequent discussion will focus on the diagnostic platforms for whole genome sequencing, ethical considerations related to diagnosis of genetic conditions and participation in gene therapy trials.
The second day of the meeting will focus on the utility of real-world data to generate real-world evidence as it pertains to neonatal research, and how C-Path’s core competencies of data science and analysis applied to real-world data promises to accelerate our understanding of some of the most challenging conditions in the neonatal population.